血液肿瘤患者大肠埃希菌基因分型及耐药现状分析

Analysis of drug resistance and genotype of Escherichia coli from patients with hematological tumor

目的:探讨血液肿瘤患者大肠埃希菌耐药性及基因型,为血液肿瘤患者合理使用抗生素提供依据。方法:采用MIC法检测大肠埃希菌对抗菌药物的敏感性,肠杆菌科基因重复性一致序列(ERIC)-聚合酶链反应(PCR)对菌株进行基因分型。结果:从血液肿瘤患者中分离出20个大肠埃希菌株,分别属于A和B2两个基因型。其中A型16株来源于痰液、血液、肺灌洗液和尿液,耐阿莫西林、头孢噻吩、庆大霉素、替卡西林、哌拉西林,耐药率均达70%以上;B2型4株来源于血液,对上述抗生素具有更高耐药率。结论:血液肿瘤患者感染的大肠埃希菌为A和B2型,具有多重耐药性。

Objective： To explore E. coli resistance and genotype from the patients with haemalogical neoplasia, provide an evidence for clinical rational use of antibiotics for haemalogical neoplasia pa-tients. Methods. MIC was used to detect the sensitivity of e. coli to antimicrobial agents. The E. coli genotyping was analyzed using enterobacteriaceae intergenic repetitive consensus sequence （ERIC）-polymerase chain reaction （PCR）. Results： 20 E. coli bacteria strains were isolated from haemalogical neoplasia patients. E. coli genotypes were type A and type B2, 16 strains were type A and 4 strains were B2. 16 type A strains were isolated from sputum, blood, lung lavage and urine samples. 4 type B2 strains came form blood samples. 16 strains of type A had a resistance to amox-icillin, cefalotin, gentamicin, westwood, the resistance rate was more than 70%. B2 type strain had a high resistance to these antibiotics compared with type A. Conclusion： Type A and B2 are main genotypes of E. coli in haemalogical neoplasia patients, they have a multi-drug resistance.